Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Rush Street Interactive Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Rush Street Interactive Inc trades at $32.29 (market cap $3.33B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | RSI | |
|---|---|---|
Market Cap | $4.49B | $3.33B |
Sector | Health | Technology |
52-Week High | $28.06 | $32.31 |
52-Week Low | $20.06 | $14.51 |
Enterprise Value | $3.69B | $3.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
RSI trades at $32.22, up 1.7% on the day, with strong technical momentum and bullish moving averages. The company reported Q1 2026 EPS of $0.14, beating estimates, and revenue growth to $1.13B in 2025. Analyst consensus is a Buy with a $29.11 target, though high P/E of 94.76 signals premium valuation. Recent news highlights operational strength and a $100M share repurchase program.
Outlook is positive given earnings beats and sector tailwinds, but risks include elevated valuation and competitive pressures. Net income margin of 2.98% remains thin, requiring sustained growth to justify multiples. Institutional sentiment is bullish, with 10 Buy ratings, supporting near-term upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
